Trial ID or NCT#

NCT00490529

Status

not recruiting iconNOT RECRUITING

Purpose

Mantle cell lymphoma (MCL) is a sub-type of non-Hodgkin's lymphoma (NHL) which is generally considered incurable with current therapy. Participants will receive an autologous vaccine against their individual lymphoma after undergoing stem cell transplantation. This vaccination may prolong the time which patients will stay in remission from their disease.

Official Title

Phase 1-2 Study of a CpG-Activated Whole Cell Vaccine Followed by Autologous "Immunotransplant" for Mantle Cell Lymphoma

Eligibility Criteria

Ages Eligible for Study: 21 Years to 70 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Michael Khodadoust
Michael Khodadoust
Assistant Professor of Medicine (Oncology) and of Dermatology
Ash A. Alizadeh, MD/PhD
Ash A. Alizadeh, MD/PhD
Moghadam Family Professor
Sandra Horning
Sally Arai
Sally Arai
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Robert Negrin
Robert Negrin
Blood and marrow transplant specialist, Hematologist, Blood and marrow transplant specialist
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Lauren Maeda
Lauren Maeda
Clinical Associate Professor, Medicine - Oncology Clinical Assistant Professor, Medicine - Hematology
Wen-Kai Weng, MD, PhD
Wen-Kai Weng, MD, PhD
Blood and marrow transplant specialist, Blood and marrow transplant specialist, Lymphoma specialist, Medical oncologist, Multiple myeloma specialist
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy) and, by courtesy, of Dermatology

Contact us to find out if this trial is right for you.

CONTACT

CCTO
(650) 498-7061